Kazia Therapeutics Ltd (NASDAQ:KZIA) (ASX:KZN) chief executive officer James Garner speaks to Proactive Investors about the oncology-focused biotech’s ongoing phase-one study of its Cantraxil treatment for ovarian cancer.
Positive summarising data from the study will be presented today at the American Association of Cancer Research annual meeting in Atlanta, GA.
“We’ve had some really good feedback actually … one of the things that’s been exciting is that in addition to the safety data we’ve presented, there’s some pointers that our drug is working,” Garner says.
He continues, “We saw more than half of the patients, actually what we call stable disease, that suggest that the drug is slowly or stopping the progression of their cancer.”